Acumen Pharmaceuticals, Inc.
ABOS
$0.988
-$0.092-8.52%
| Weiss Ratings | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.96 | |||
| Price History | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -16.97% | |||
| 30-Day Total Return | -28.41% | |||
| 60-Day Total Return | -46.59% | |||
| 90-Day Total Return | -58.31% | |||
| Year to Date Total Return | -46.59% | |||
| 1-Year Total Return | -74.73% | |||
| 2-Year Total Return | -77.08% | |||
| 3-Year Total Return | -75.84% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -73.40% | |||
| 52-Week Low % Change | 2.86% | |||
| Price | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.06 | |||
| 52-Week Low Price | $1.05 | |||
| 52-Week Low Price (Date) | Apr 02, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 65.42M | |||
| Enterprise Value | -136.40M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.70 | |||
| Earnings Per Share Growth | 57.53% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.36 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.99 | |||
| Enterprise Value/EBITDA (TTM) | 1.20 | |||
| Enterprise Value/EBIT | 1.20 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 60.08M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 434 297 1000 | |||
| Address | 427 Park Street Charlottesville, VA 22902 | |||
| Website | acumenpharm.com | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.95% | |||
| Return on Equity | -- | |||
| Income Statement | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -124.07M | |||
| EBITDA (TTM) | -113.95M | |||
| EBIT (TTM) | -114.02M | |||
| Net Income (TTM) | -102.33M | |||
| Net Income Avl. to Common (TTM) | -102.33M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -125.22% | |||
| EPS Diluted (TTM) | -1.70 | |||
| EPS Diluted Growth (Q YOY) | -117.44% | |||
| Balance Sheet | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 171.56M | |||
| Cash Per Share (Q) | $2.86 | |||
| Total Current Assets (Q) | 178.31M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 181.82M | |||
| Current Ratio (Q) | 6.459 | |||
| Book Value Per Share (Q) | $3.03 | |||
| Total Assets (Q) | 238.99M | |||
| Total Current Liabilities (Q) | 27.61M | |||
| Total Debt (Q) | 29.70M | |||
| Total Liabilities (Q) | 57.18M | |||
| Total Common Equity (Q) | 181.82M | |||
| Cash Flow | ABOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 48.03M | |||
| Cash from Financing (TTM) | 6.93M | |||
| Net Change in Cash (TTM) | -31.26M | |||
| Levered Free Cash Flow (TTM) | -52.29M | |||
| Cash from Operations (TTM) | -86.22M | |||
